Filtered By:
Source: European Heart Journal
Condition: Intermittent Claudication
Drug: Warfarin

This page shows you your search results in order of date.

Order by Relevance | Date

Total 1 results found since Jan 2013.

Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF
Conclusion Patients with PAD in ROCKET AF did not have a statistically significant higher risk of stroke or systemic embolism than patients without PAD, and there were similar efficacy outcomes in patients treated with rivaroxaban and warfarin. In PAD patients, there was a higher risk of major bleeding or NMCR bleeding with rivaroxaban when compared with warfarin (interaction P = 0.037). Further investigation is warranted to validate this subgroup analysis and determine the optimal treatment in this high-risk cohort of AF patients with PAD.
Source: European Heart Journal - January 21, 2014 Category: Cardiology Authors: Jones, W. S., Hellkamp, A. S., Halperin, J., Piccini, J. P., Breithardt, G., Singer, D. E., Fox, K. A. A., Hankey, G. J., Mahaffey, K. W., Califf, R. M., Patel, M. R. Tags: Atrial fibrillation Source Type: research